A New Collaboration Could Be Key in the Early Detection of Lung Cancer

A newly-formed partnership between Biodesix and MRM Proteomics could be the key that unlocks the door for better outcomes in lung cancer patients. Earlier this week, the two diagnostic companies announced a deal that would have Montreal-based MRM Proteomics granting Biodesix the rights to use the iMALDI technologies.